| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1378680 | Bioorganic & Medicinal Chemistry Letters | 2006 | 6 Pages |
Abstract
The synthesis, structure–activity relationship, in vivo activity, and metabolic profile for a series of triazolopyridine-oxazole based p38 inhibitors are described. The deficiencies of the lead structure in the series, CP-808844, were overcome by changes to the C4 aryl group and the triazole side-chain culminating in the identification of several potential clinical candidates.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Kim F. McClure, Michael A. Letavic, Amit S. Kalgutkar, Christopher A. Gabel, Laurent Audoly, John T. Barberia, John F. Braganza, Demetrius Carter, Thomas J. Carty, Santo R. Cortina, Mark A. Dombroski, Kathleen M. Donahue, Nancy C. Elliott,